Biopharma Dealmaking Quarterly Statistics, Q2 2013
A look at the financing, M&A, and alliance activity April-June 2013
Executive Summary
Q2 2013 biopharma financing increased 139% to $11 billion over Q1’s $4.6 billion, thanks mostly to two huge transactions by Valeant to fund its $8.7 billion takeover of ophthalmics player Bausch & Lomb, the company’s largest acquisition to date. Options and antibody-drug conjugates featured prominently in the alliances.